[go: up one dir, main page]

WO2003028624A3 - Compositions de levothyroxine et procedes - Google Patents

Compositions de levothyroxine et procedes Download PDF

Info

Publication number
WO2003028624A3
WO2003028624A3 PCT/US2002/025752 US0225752W WO03028624A3 WO 2003028624 A3 WO2003028624 A3 WO 2003028624A3 US 0225752 W US0225752 W US 0225752W WO 03028624 A3 WO03028624 A3 WO 03028624A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
sodium
making
levothyroxine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/025752
Other languages
English (en)
Other versions
WO2003028624A2 (fr
Inventor
G Andrew Franz
Elaine A Strauss
Phillip A Dimenna
Rocco L Gemma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King Pharmaceuticals Inc
Original Assignee
King Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc filed Critical King Pharmaceuticals Inc
Priority to AU2002362468A priority Critical patent/AU2002362468A1/en
Publication of WO2003028624A2 publication Critical patent/WO2003028624A2/fr
Publication of WO2003028624A3 publication Critical patent/WO2003028624A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte en général sur des compositions pharmaceutiques et sur leurs procédés de fabrication et d'administration. Selon une forme d'exécution, l'invention se caractérise par des compositions pharmaceutiques stabilisées qui comprennent des ingrédients actifs d'un point de vue pharmaceutique tels que lévothyroxine (T4) sodium et liothyronine (T3) sodium (médicaments de l'hormone thyroïdienne), de préférence de forme galénique solide à libération immédiate. L'invention porte également sur des procédés de fabrication et d'utilisation de ces compositions stabilisées et à libération immédiate.
PCT/US2002/025752 2001-08-14 2002-08-14 Compositions de levothyroxine et procedes Ceased WO2003028624A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362468A AU2002362468A1 (en) 2001-08-14 2002-08-14 Levothyroxine compositions and methods

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US31248301P 2001-08-14 2001-08-14
US31227301P 2001-08-14 2001-08-14
US31218401P 2001-08-14 2001-08-14
US31211401P 2001-08-14 2001-08-14
US31228701P 2001-08-14 2001-08-14
US31211301P 2001-08-14 2001-08-14
US60/312,114 2001-08-14
US60/312,184 2001-08-14
US60/312,113 2001-08-14
US60/312,287 2001-08-14
US60/312,273 2001-08-14

Publications (2)

Publication Number Publication Date
WO2003028624A2 WO2003028624A2 (fr) 2003-04-10
WO2003028624A3 true WO2003028624A3 (fr) 2003-11-06

Family

ID=27617967

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/025854 Ceased WO2003061557A2 (fr) 2001-08-14 2002-08-14 Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees
PCT/US2002/025752 Ceased WO2003028624A2 (fr) 2001-08-14 2002-08-14 Compositions de levothyroxine et procedes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025854 Ceased WO2003061557A2 (fr) 2001-08-14 2002-08-14 Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees

Country Status (2)

Country Link
AU (1) AU2002341555A1 (fr)
WO (2) WO2003061557A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
KR20060109926A (ko) 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
EP3541395A4 (fr) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. Méthodes de traitement de glycogénose
JP7168660B2 (ja) 2017-06-05 2022-11-09 バイキング・セラピューティクス・インコーポレイテッド 線維症の処置のための組成物
MX2020009843A (es) 2018-03-22 2020-12-11 Viking Therapeutics Inc Formas cristalinas y metodos de produccion de formas cristalinas de un compuesto.
WO2020117962A1 (fr) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions pour le traitement de la fibrose et de l'inflammation
EP4360705A3 (fr) * 2020-01-13 2024-07-10 Amneal Complex Products Research LLC Compositions à libération prolongée comprenant de la liothyronine
US11964048B2 (en) 2020-12-18 2024-04-23 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753254A (en) * 1994-02-01 1998-05-19 Knoll Aktiengesellschaft Therapeutic agents containing thyroid hormones
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA98003802A (es) * 1995-11-14 2005-04-29 Abbott Gmbh & Co Kg Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753254A (en) * 1994-02-01 1998-05-19 Knoll Aktiengesellschaft Therapeutic agents containing thyroid hormones
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions

Also Published As

Publication number Publication date
WO2003061557A2 (fr) 2003-07-31
WO2003028624A2 (fr) 2003-04-10
WO2003061557A3 (fr) 2003-11-06
AU2002341555A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2002017918A3 (fr) Formulations a liberation prolongee pour les secretagogues de l'hormone de croissance
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
PT1412384E (pt) Formulação estável de glp-1 modificado
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2002074247A8 (fr) Formulations pharmaceutiques a liberation prolongee
WO2001085257A3 (fr) Compositions d'antagoniste opioide et formes de dosage
EA017764B8 (ru) Фармацевтическая композиция, способ ее получения и способ лечения вирусных заболеваний с ее использованием
ZA200410109B (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability.
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
IL150528A0 (en) Ibuprofen containing active agent preparation
MY151468A (en) Controlled release solid preparation
WO2003028624A3 (fr) Compositions de levothyroxine et procedes
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
AP2003002763A0 (en) Controlled release formulations for oral administration
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
WO2002015933A3 (fr) Combinaison
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
WO2003013441A3 (fr) Compositions de levothyroxine et procedes connexes
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
WO2004014318A3 (fr) Compositions de levothyroxine et procedes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP